D. Zabolotnyy

Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer

Jan B. Vermorken, Fernando Rivera, Éva Remenár et al. · New England Journal of Medicine · 2008 · 3.7K citations · Full text

Medicine, Oncology, Pharmacology +16

Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study

Lisa Licitra, Fernando Rivera, Éva Remenár et al. · Annals of Oncology · 2010 · 230 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil (5-FU) in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R&M SCCHN) (EXTREME)

J. B. Vermorken, M. E. Vega-Villegas, Éva Remenár et al. · Journal of Clinical Oncology · 2006 · 21 citations

Medicine, Oncology, Pharmacology +17

5501 ORAL Cetuximab plus platinum-based therapy first-line in recurrent and/or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): Efficacy and safety results of a randomized phase III trial (EXTREME)

Jan B. Vermorken, Ricardo Hitt, Lionnel Geoffrois et al. · European Journal of Cancer Supplements · 2007 · 18 citations

Medicine, Oncology, Cancer Pharmacology +7